Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:44 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025)
NCT01609231 · Merck Sharp & Dohme LLC · PHASE2 · terminated · last registry update 2020-05-04 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “This trial was halted prematurely for business reasons and low enrollment.” | – | Registry record, Merck Sharp & Dohme LLC |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IGF1R within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-02-21Results posted on the registry: Amgen, Modified FOLFOX6 + Conatumumab (NCT01327612)
- 2021-01-20Results posted on the registry: Children's Hospital Medical Center, Cincinnati, IGF-1 (NCT01207908)
- 2020-12-10Also stopped (terminated): Pfizer, MEK162 + AMG 479 (NCT01562899)
- 2020-08-14Also stopped (terminated): Ipsen, rh IGF-1 (mecasermin) (NCT00330668)
- 2020-08-11Also stopped (terminated): Bristol-Myers Squibb, BMS-754807 + letrozole (NCT01225172)
- 2020-07-17Results posted on the registry: Massachusetts General Hospital, rhIGF-1 + Risedronate (NCT01406444)
- 2020-03-10Results posted on the registry: Amgen, Teprotumumab (NCT03298867)
- 2019-07-11Results posted on the registry: Bristol-Myers Squibb, BMS-754807 + letrozole (NCT01225172)
- 2019-07-09Results posted on the registry: Cedars-Sinai Medical Center, a drug against IGF1R (NCT00915954)
- 2019-06-03Results posted on the registry: University of Oxford, Linsitinib (NCT02546544)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision